Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

EZH2 in normal and malignant hematopoiesis.

Lund K, Adams PD, Copland M.

Leukemia. 2014 Jan;28(1):44-9. doi: 10.1038/leu.2013.288. Epub 2013 Oct 7. Review.

PMID:
24097338
2.

EZH2 in normal hematopoiesis and hematological malignancies.

Herviou L, Cavalli G, Cartron G, Klein B, Moreaux J.

Oncotarget. 2016 Jan 19;7(3):2284-96. doi: 10.18632/oncotarget.6198. Review.

3.

Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.

Sashida G, Iwama A.

Int J Hematol. 2017 Jan;105(1):23-30. doi: 10.1007/s12185-016-2124-x. Epub 2016 Nov 9. Review.

PMID:
27830540
4.

Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner.

Mochizuki-Kashio M, Aoyama K, Sashida G, Oshima M, Tomioka T, Muto T, Wang C, Iwama A.

Blood. 2015 Sep 3;126(10):1172-83. doi: 10.1182/blood-2015-03-634428. Epub 2015 Jul 28.

5.

Overexpression of enhancer of zests homolog 2 in lymphoma.

Guo SQ, Zhang YZ.

Chin Med J (Engl). 2012 Oct;125(20):3735-9. Review.

PMID:
23075734
6.

Targeting EZH2 and PRC2 dependence as novel anticancer therapy.

Xu B, Konze KD, Jin J, Wang GG.

Exp Hematol. 2015 Aug;43(8):698-712. doi: 10.1016/j.exphem.2015.05.001. Epub 2015 May 28. Review.

7.

Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.

Khan SN, Jankowska AM, Mahfouz R, Dunbar AJ, Sugimoto Y, Hosono N, Hu Z, Cheriyath V, Vatolin S, Przychodzen B, Reu FJ, Saunthararajah Y, O'Keefe C, Sekeres MA, List AF, Moliterno AR, McDevitt MA, Maciejewski JP, Makishima H.

Leukemia. 2013 Jun;27(6):1301-9. doi: 10.1038/leu.2013.80. Epub 2013 Mar 14.

PMID:
23486531
8.

Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.

Gall TroĊĦelj K, Novak Kujundzic R, Ugarkovic D.

Clin Epigenetics. 2016 May 27;8:55. doi: 10.1186/s13148-016-0226-1. eCollection 2016. Review.

9.

Double sword role of EZH2 in leukemia.

Safaei S, Baradaran B, Hagh MF, Alivand MR, Talebi M, Gharibi T, Solali S.

Biomed Pharmacother. 2018 Feb;98:626-635. doi: 10.1016/j.biopha.2017.12.059. Epub 2017 Dec 29. Review.

PMID:
29289837
10.

EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter.

van Vlerken LE, Kiefer CM, Morehouse C, Li Y, Groves C, Wilson SD, Yao Y, Hollingsworth RE, Hurt EM.

Stem Cells Transl Med. 2013 Jan;2(1):43-52. doi: 10.5966/sctm.2012-0036. Epub 2012 Dec 27.

11.

Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase.

Ott M, Litzenburger UM, Sahm F, Rauschenbach KJ, Tudoran R, Hartmann C, Marquez VE, von Deimling A, Wick W, Platten M.

PLoS One. 2012;7(10):e47663. doi: 10.1371/journal.pone.0047663. Epub 2012 Oct 15.

12.

Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.

Chen J, Li J, Han Q, Sun Z, Wang J, Wang S, Zhao RC.

Exp Biol Med (Maywood). 2012 Sep;237(9):1110-6. Epub 2012 Sep 6.

PMID:
22956625
13.

EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes.

Hernando H, Gelato KA, Lesche R, Beckmann G, Koehr S, Otto S, Steigemann P, Stresemann C.

Mol Cancer Ther. 2016 Feb;15(2):287-98. doi: 10.1158/1535-7163.MCT-15-0486. Epub 2015 Nov 20.

14.

Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells.

Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, Oh YT, Kim H, Rheey J, Nakano I, Lee C, Joo KM, Rich JN, Nam DH, Lee J.

Cancer Cell. 2013 Jun 10;23(6):839-52. doi: 10.1016/j.ccr.2013.04.008. Epub 2013 May 16.

15.

Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.

Kikuchi J, Takashina T, Kinoshita I, Kikuchi E, Shimizu Y, Sakakibara-Konishi J, Oizumi S, Marquez VE, Nishimura M, Dosaka-Akita H.

Lung Cancer. 2012 Nov;78(2):138-43. doi: 10.1016/j.lungcan.2012.08.003. Epub 2012 Aug 25.

16.

Targeting histone methyltransferase EZH2 as cancer treatment.

Kondo Y.

J Biochem. 2014 Nov;156(5):249-57. doi: 10.1093/jb/mvu054. Epub 2014 Aug 31. Review.

PMID:
25179367
17.

EZH2: not EZHY (easy) to deal.

Deb G, Singh AK, Gupta S.

Mol Cancer Res. 2014 May;12(5):639-53. doi: 10.1158/1541-7786.MCR-13-0546. Epub 2014 Feb 13. Review.

18.

Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.

Shiogama S, Yoshiba S, Soga D, Motohashi H, Shintani S.

Anticancer Res. 2013 Oct;33(10):4309-17.

PMID:
24122997
19.

Deletion of the Polycomb-Group Protein EZH2 Leads to Compromised Self-Renewal and Differentiation Defects in Human Embryonic Stem Cells.

Collinson A, Collier AJ, Morgan NP, Sienerth AR, Chandra T, Andrews S, Rugg-Gunn PJ.

Cell Rep. 2016 Dec 6;17(10):2700-2714. doi: 10.1016/j.celrep.2016.11.032.

20.

A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.

Ott HM, Graves AP, Pappalardi MB, Huddleston M, Halsey WS, Hughes AM, Groy A, Dul E, Jiang Y, Bai Y, Annan R, Verma SK, Knight SD, Kruger RG, Dhanak D, Schwartz B, Tummino PJ, Creasy CL, McCabe MT.

Mol Cancer Ther. 2014 Dec;13(12):3062-73. doi: 10.1158/1535-7163.MCT-13-0876. Epub 2014 Sep 24.

Supplemental Content

Support Center